CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total UpHealth, Inc. Stockholders’ Equity	Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	[1]				0
Balance at beginning of period (in shares) at Dec. 31, 2021	[1]		14,428
Balance at beginning of period at Dec. 31, 2021	[1]	$ 333,843	$ 1	$ 665,474	$ 0	$ (343,209)	$ (3,802)	$ 318,464	$ 15,379
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)	[1]		37
Equity award activity, net of shares withheld for taxes	[1]	(67)		(67)				(67)
Stock-based compensation		1,374		1,374				1,374
Net loss		(17,705)				(17,445)		(17,445)	(260)
Foreign currency translation adjustments		(1,377)					(1,377)	(1,377)
Balance at end of period (in shares) at Mar. 31, 2022	[1]		14,465
Balance at end of period (in shares) at Mar. 31, 2022	[1]				0
Balance at end of period at Mar. 31, 2022	[1]	316,068	$ 1	666,781	$ 0	(360,654)	(5,179)	300,949	15,119
Balance at beginning of period (in shares) at Dec. 31, 2021	[1]		14,428
Balance at beginning of period at Dec. 31, 2021	[1]	333,843	$ 1	665,474	$ 0	(343,209)	(3,802)	318,464	15,379
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(30,170)
Foreign currency translation adjustments		(3,857)
Balance at end of period (in shares) at Jun. 30, 2022	[1]		14,685
Balance at end of period (in shares) at Jun. 30, 2022	[1]				170
Balance at end of period at Jun. 30, 2022	[1]	300,884	$ 2	683,710	$ (17,000)	(373,092)	(7,659)	285,961	14,923
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	[1]				0
Balance at beginning of period (in shares) at Mar. 31, 2022	[1]		14,465
Balance at beginning of period at Mar. 31, 2022	[1]	316,068	$ 1	666,781	$ 0	(360,654)	(5,179)	300,949	15,119
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)	[1]		390
Equity award activity, net of shares withheld for taxes	[1]	(1,158)	$ 1	(1,159)				(1,158)
Stock-based compensation		1,088		1,088				1,088
Common stock repurchased in connection with forward share purchase agreement (in shares)	[1]		(170)		170
Common stock repurchased in connection with forward share purchase agreement	[1]	0		17,000	$ (17,000)
Purchase of noncontrolling interest		(30)							(30)
Distribution to noncontrolling interests		(139)							(139)
Net loss		(12,465)				(12,438)		(12,438)	(27)
Foreign currency translation adjustments		(2,480)					(2,480)	(2,480)
Balance at end of period (in shares) at Jun. 30, 2022	[1]		14,685
Balance at end of period (in shares) at Jun. 30, 2022	[1]				170
Balance at end of period at Jun. 30, 2022	[1]	300,884	$ 2	683,710	$ (17,000)	(373,092)	$ (7,659)	285,961	14,923
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	[1]				170
Balance at beginning of period (in shares)					170
Balance at beginning of period (in shares) at Dec. 31, 2022			15,054
Balance at beginning of period at Dec. 31, 2022		106,137	$ 2	688,355	$ (17,000)	(566,209)		105,148	989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)			80
Equity award activity, net of shares withheld for taxes		(3)		(3)				(3)
Issuance of common stock in connection with 2023 private placement, net of issuance costs of $348 (in shares)			1,650
Issuance of common stock in connection with 2023 private placement, net of issuance costs of $348		4,155		4,155				4,155
Stock-based compensation		989		989				989
Distribution to noncontrolling interests		(44)							(44)
Net loss		(7,635)				(8,083)		(8,083)	448
Balance at end of period (in shares) at Mar. 31, 2023			16,784
Balance at end of period (in shares) at Mar. 31, 2023					170
Balance at end of period at Mar. 31, 2023		103,599	$ 2	693,496	$ (17,000)	(574,292)		102,206	1,393
Balance at beginning of period (in shares) at Dec. 31, 2022			15,054
Balance at beginning of period at Dec. 31, 2022		106,137	$ 2	688,355	$ (17,000)	(566,209)		105,148	989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(26,254)
Foreign currency translation adjustments		0
Balance at end of period (in shares) at Jun. 30, 2023			17,161
Balance at end of period (in shares) at Jun. 30, 2023					170
Balance at end of period at Jun. 30, 2023		85,415	$ 2	694,554	$ (17,000)	(593,419)		84,137	1,278
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)					170
Balance at beginning of period (in shares) at Mar. 31, 2023			16,784
Balance at beginning of period at Mar. 31, 2023		103,599	$ 2	693,496	$ (17,000)	(574,292)		102,206	1,393
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)			277
Equity award activity, net of shares withheld for taxes		0
Exercise of pre-funded warrants (in shares)			100
Stock-based compensation		1,058		1,058				1,058
Distribution to noncontrolling interests		(623)							(623)
Net loss		(18,619)				(19,127)		(19,127)	508
Foreign currency translation adjustments		0
Balance at end of period (in shares) at Jun. 30, 2023			17,161
Balance at end of period (in shares) at Jun. 30, 2023					170
Balance at end of period at Jun. 30, 2023		$ 85,415	$ 2	$ 694,554	$ (17,000)	$ (593,419)		$ 84,137	$ 1,278
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)					170

[1] Amounts as of June 30, 2022 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022.